NCT07175441 - Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

August 31, 2027

Conditions

Advanced Unresectable Hepatocellular Carcinoma

Interventions

DRUG

RBS2418

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.

DRUG

STRIDE (durvalumab + tremelimumab)

STRIDE: Tremelimumab 300 mg IV (Cycle 1 Day 1 only) Plus Durvalumab 1500 mg IV every 4 weeks

Trial Locations (1)

21218

Johns Hopkins, Baltimore

All Listed Sponsors

lead

Riboscience, LLC.

INDUSTRY